Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors
Authors:
- Diwakar DavarDDDiwakar Davar
- Benedito A CarneiroBCBenedito A Carneiro
- Grace K DyGDGrace K Dy
- Siddharth ShethSSSiddharth Sheth
- Mitesh J BoradMBMitesh J Borad
- Kevin J HarringtonKHKevin J Harrington
- Sandip P PatelSPSandip P Patel
- Evanthia GalanisEGEvanthia Galanis
- Adel SamsonASAdel Samson
- Sonia AgrawalSASonia Agrawal
- Zhongying ChenZCZhongying Chen
- Chunling FanCFChunling Fan
Open Access
- 17 November 2024
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (11) , e009336
Abstract
Background: MEDI5395 is a recombinant attenuated Newcastle disease virus engineered to express a human granulocyte-macrophage colony-stimulating factor transgene. Preclinically, MEDI5395 demonstrated broad oncolytic activity, augmented by concomitant programmed cell death-1/programmed cell death ligand-1 (PD-L1) axis blockade. Durvalumab is an anti-PD-L1 immune checkpoint inhibitor approved for the treatment of various solid tumors. We describe the results of the first-in-human study combining intravenous MEDI5395 with durvalumab in patients with advanced solid tumors. Methods: This phase I, open-label, multicenter, dose-escalation, dose-expansion study recruited adult patients with advanced solid tumors, who had relapsed or were refractory or intolerant to ≥1 prior line of standard treatment. MEDI5395 was administered intravenously as six doses over 15–18 days. The dose-escalation phase assessed four-dose levels (108, 109, 1010, 1011 focus forming units (FFU)) of MEDI5395, with sequential or delayed durvalumab. Durvalumab 1500 mg was administered intravenously every 4 weeks up to 2 years. The dose-expansion phase was not initiated. The primary objectives were to evaluate safety and tolerability, dose-limiting toxicities (DLTs) and the dose and schedule of MEDI5395 plus durvalumab administration. Secondary objectives included the assessment of the efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MEDI5395. Results: 39 patients were treated with MEDI5395; 36 patients also received durvalumab. All 39 patients experienced ≥1 treatment-emergent adverse event (TEAE), most commonly fatigue (61.5%), nausea (53.8%) and chills (51.3%). Grade 3–4 TEAEs occurred in 27 (69.2%) patients; these were deemed MEDI5395-related in 12 (30.8%) patients. Two patients experienced a DLT, and the maximum tolerated dose of MEDI5395 with sequential and delayed durvalumab at study termination was 1011 and 1010 FFU, respectively. Four patients (10.3%) achieved a partial response (PR). Patients with PR or stable disease tended to have higher baseline PD-L1 and CD8+ levels in their tumor tissue. A tendency to dose-dependent pharmacokinetics of the viral genome was observed in whole blood and a tendency to dose-dependent viral shedding was observed in saliva and urine. Neutralizing antibodies were observed in all patients but did not appear to impact efficacy negatively. Conclusion: This study demonstrates the feasibility, safety and preliminary efficacy of MEDI5395 with durvalumab in patients with advanced solid tumors. Trial registration number: NCT03889275Keywords
Funding Information
- AstraZeneca (N/A)
This publication has 44 references indexed in Scilit:
- Integrating innate and adaptive immunity in oncolytic virus therapyTrends in Cancer, 2023
- Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitroCancer Immunology, Immunotherapy, 2020
- In vitro infectivity of oncolytic Newcastle Disease Virus: Correlation between plaque and fluorescent focus assaysJournal of Virological Methods, 2018
- Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)European Journal of Cancer, 2017
- Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyCell, 2017
- A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2Contemporary Clinical Trials, 2017
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic VirusMolecular Therapy, 2014
- Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humansNature, 2011
- B7-H1 pathway and its role in the evasion of tumor immunityJournal of Molecular Medicine, 2003